Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price TargetNEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.90 following the Company's release of first-half fiscal year 2026 financial results and strategic update.
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps ConferenceMELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March 2026 (11:00am – 11:30am Australian Eastern Time).
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price TargetNEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.50 following the Company's release of first-half fiscal year 2026 operating results.
Immuron Announces Clinical Trial UpdateMELBOURNE, Australia, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company provides a clinical trial update on Travelan® and IMM-529.
Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price TargetNew York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on...
Immuron Q1 FY26 YoY growthSales Highlights (unaudited):
Immuron partners with InvestorHubMELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors.
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron’s product portfolio which includes the rapidly growing Travelan® brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend.
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5thCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand ViewingNEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing.
Small Cap Growth Virtual Investor Conference Agenda Announced for December 5thCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5thMELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com on Thursday 5th December 2024 (2.30pm U.S. Eastern time).
